Indivior stock falls after terminating Reckitt Benckiser supply deal

Indivior Pharmaceuticals, Inc. stock (ISIN GB00BYZ0C031) closed at USD 34.22 on Nasdaq on September 15, 2026, down 0.73% for the day and leaving the shares about 43.2 percent below the average analyst price target of USD 49.00 as of that date, according to Indivior overviews on MarketScreener data.

Supply agreement with Reckitt Benckiser ends

As MarketScreener reported on September 16, 2026, Indivior has terminated its manufacturing and supply agreement with consumer goods group Reckitt Benckiser, marking a strategic step in reshaping its production arrangements.

According to MarketScreener, the move follows a busy summer for Indivior that included a planned all-stock merger with Supernus Pharmaceuticals and a proposal for a special cash dividend, underlining how actively the company is reshaping its portfolio and capital structure.

Second quarter results and 2026 guidance

According to MarketScreener, Indivior reported net revenue of USD 343.0 million in the second quarter of 2026, which came in above the FactSet consensus estimate of USD 307.6 million for the period ended June 30, 2026.

The same overview from MarketScreener notes that Indivior raised its 2026 net revenue guidance, now expecting net revenue between USD 1.30 billion and USD 1.37 billion versus earlier expectations around USD 1.26 billion based on FactSet estimates, implying potential growth of roughly 3.2 percent to 8.7 percent against that benchmark.

For investors, the combination of a supply agreement exit and an upgraded revenue outlook means Indivior is aiming to improve profitability and control over its manufacturing base while still pointing to continued top-line expansion in its core addiction-treatment franchises.

Analyst consensus and valuation backdrop

According to consensus data compiled by MarketScreener, four analysts currently cover Indivior and the average recommendation stands at Buy, with an average price target of USD 49.00.

With the last closing price at USD 34.22 on September 15, 2026, this average target implies upside of about 43.2 percent if the stock were to move in line with analyst expectations, underscoring the gap between the market price and the consensus valuation.

The same source shows that Indivior had declined modestly year to date, with a performance of around minus 4.63 percent as of mid-September 2026, even as its earnings revisions and guidance have been moving upward, a pattern that can present an opportunity but also signals that investors remain cautious about execution and regulatory risks in addiction-treatment markets.

Stock level and market metrics

Per the Indivior overview on MarketScreener, Indivior shares trade on Nasdaq under the ticker INDV, with the closing price of USD 34.22 on September 15, 2026.

The same price snapshot indicates that the stock remained within its established 52-week trading range at that date and had posted a five-day percentage change of minus 0.29 percent alongside the year-to-date move of minus 4.63 percent, while the market capitalization stood in the multi-billion dollar range as of mid-September 2026.

For retail investors, the combination of a clearly defined analyst upside, updated revenue guidance and modest recent share-price weakness forms a backdrop in which the termination of the Reckitt Benckiser agreement is an important operational milestone but not the only driver of Indivior stock as of September 16, 2026.

More news and analyses on Indivior stock